Related Experiment Video
Updated: May 3, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and
Shahla Shahsavandi1, Sina Soleimani1, Majid Tebyanian1
1Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Background And Objectives:
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has presented a challenging issue for global health in the 21st century. Frequent mutations in viral genomes have diminished the effectiveness of current vaccines against new variants. Messenger RNA (mRNA) vaccine is a promising platform for eliciting a robust T cell immune response.
Materials And Methods:
We evaluated the uptake of mRNA-LNPs into human monocyte-derived dendritic cells by measuring the intensity of enhanced eGFP expression in the transfected cells. Next, we assessed the effect of mRNA-LNPs on immune response induction in mice following a prime-boost immunization strategy, along with analyzing cytokine release. The safety of the vaccine candidate was examined through pyrogenicity and toxicity assays.
Results:
Upon intramuscular injection of mice, potent antibodies specific to viral S protein, robust Th1-biased cell-mediated immunity, and enhanced IFN-γ expression were induced. These observations indicate that mRNA-LNP was taken up and that it migrated to the lymph nodes. Furthermore, the vaccine candidate did not cause inflammation or local reactions after injection, as confirmed by biochemical, hematological, and histopathological examinations.
Conclusion:
Because of its ability to target immune cells, the mRNA vaccine candidate can potentially improve immune responses against circulating or emerging variants.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
06:08Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
Related Concept Videos
Viral Mutations
Leaky Scanning
Single Nucleotide Polymorphisms-SNPs
Viruses with RNA Genomes